Previous Workshops 10-11 May 2012, Baltimore, MD, USA This meeting brought together experts from the biological industry, academia and regulatory agencies to review the possibility of introducing new selected biomarkers in the assessment of vaccine safety at pre-clinical and early clinical stages (inflammation and early immunological events). The goal of the meeting was to facilitate the integration of recent scientific advances into vaccine regulatory processes. New Cells, New Vaccines VI, the latest conference in a series that began in 2005, will be of interest to scientists in the biotechnology and pharmaceutical industries involved in vaccine development and production, as well as academics, regulatory and public health authorities, and medical and veterinary experts. The venue and the meeting provide a perfect opportunity to interact with colleagues from industry, academia and regulatory agencies to exchange views and ideas and explore potential collaboration. The goal of this workshop was to review traditional and new technology for the detection of microbial agents; to consider how progress in microbial agent detection can assist in ensuring the safety of starting materials and final products; and to consider how risk assessment can help to address safety issues.
The purpose of the meeting was to present the current scientific status on the development and
The workshop aimed at reviewing the present knowledge on Mode of Action (MoA) of Adjuvants, evaluate how progress in the “adjuvant science” can help define appropriate vaccine design, and evaluate how understanding of adjuvants MoA can help to address safety issues. |
Organized by ![]() Become an IABS Member Add to Calendar http://markers-of-adjuvant-safety-2013.iabs.org/ 18-04-2013 07:30:00 19-04-2013 15:45:00 15 International Workshop - Adjuvant Safety Predictive Markers of Adjuvant Safety and Immunology Rockville, Maryland, USA IABS markers-of-adjuvant-safety-2013@dodetbioscience.com false ![]() ![]() Gold Sponsors ![]() Silver Sponsors ![]() ![]() |